Newsroom

Sorted by: Latest

-

Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of December 18, 2025: Total number of shares outstanding:       92,197,823 ordinary shares...
-

Nouveau nombre d’actions et de droits de vote d’Innate Pharma au 18 décembre 2025

MARSEILLE, France--(BUSINESS WIRE)--Regulatory news: Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 18 décembre 2025 : Nombre d’actions composant le capital :       92 197 823 actions ordinaires         6 324 Actio...
-

FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved CD20xCD3 bispecific Lunsumio VELO™ (mosunetuzumab-axgb), as a subcutaneous (SC) formulation, for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy, based on results from the Phase I/II GO29781 study. Based on the study re...
-

GenSight Biologics annonce la délivrance d’une autorisation d’accès compassionnel (AAC) pour GS010/LUMEVOQ® en France

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), une société biopharmaceutique spécialisée dans le développement et la commercialisation de thérapies géniques pour les maladies neurodégénératives de la rétine et les troubles du système nerveux central, annonce aujourd’hui que l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) a autorisé un accès compassionnel (Autorisation d’Accès Compassionnel, AAC)...
-

GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the French medicines safety agency ANSM (Agence nationale de sécurité du médicament et des produits de santé) has granted compassionate use authorization (Autorisation d’Accès Compassionnel, or AA...
-

e.l.f. Cosmetics Extends Partnership with The Wonder Women of Wrestling Foundation

OAKLAND, Calif.--(BUSINESS WIRE)--e.l.f. Cosmetics, a brand from e.l.f. Beauty (NYSE: ELF), the bold disruptor with a kind heart, today announced the extension of its partnership with The Wonder Women of Wrestling Foundation (WWOWF) for a second consecutive year. e.l.f. returns as the first-ever beauty sponsor of the WWOWF Varsity Girls Wrestling Tournament on December 29-30, 2025, in Columbia, Missouri. This continued partnership reinforces e.l.f.’s commitment to leveling the playing field for...
-

QAD | Redzone Marks 20 Years in India by Honoring 2025 Champions of Change Driving the Future of Manufacturing

MUMBAI, India--(BUSINESS WIRE)--QAD | Redzone, the company redefining manufacturing and supply chains through intelligent, adaptive solutions, today announced the winners of the 2025 QAD | Redzone India Champions of Change Awards at Champions of Manufacturing India in Mumbai. The awards honor customers and partners who are setting new benchmarks for execution, speed, and scale across one of the world’s most dynamic manufacturing markets—coinciding with QAD | Redzone’s 20-year milestone in India...
-

海信加入 HEVC Advance 专利池

马萨诸塞州波士顿--(BUSINESS WIRE)--(美国商业资讯)-- 视频编解码器专利池许可的全球领导者Access Advance LLC今日宣布,海信集团控股有限公司已作为被许可方加入 HEVC Advance 专利池。海信是众多最近加入Access Advance专利池的新成员之一,这些新近加入的成员包括包括小米、微星科技、传音,以及扩大与Access Advance合作关系的华为、惠普和夏普。 海信总部位于中国青岛,是全球最大的电视制造商之一,业务遍及亚洲、欧洲、美洲等地,该公司的产品销往全球160多个国家和地区。 Access Advance 首席执行官 Peter Moller 表示:“我们很高兴地欢迎海信加入 HEVC Advance 专利池。“这项协议是我们双方的团队在相当长一段时间内深入交流的结果。海信加入专利池的决定,反映了大家认识到,透明、高效的许可解决方案对整个视频技术生态系统的创新者和实施者都有益处。 通过加入 HEVC Advance 专利池,海信仅凭单一许可协议获得了实施 HEVC/H.265 标准所需的数万项必要专利。该专利池根据公平、合理和非歧视...
-

Hisense Joins HEVC Advance Patent Pool

BOSTON--(BUSINESS WIRE)--Access Advance LLC today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee....
-

HisenseがHEVC Advance特許プールに参加

マサチューセッツ州ボストン--(BUSINESS WIRE)--(ビジネスワイヤ) -- ビデオコーデック特許プールライセンスの世界的リーダーであるAccess Advance LLCは本日、Hisense Group Holdings Co., Ltd.がライセンシーとしてHEVC Advance特許プールに加わったことを発表しました。Hisenseは、最近加入したXiaomi、MSI、Transsionや、関係を拡大したHuawei、HP、Sharpなどに引き続き、Access Advance特許プール加わりました。 中国青島に本社を置くHisenseは、アジア、ヨーロッパ、南北アメリカ、そして更に拡大する世界的なプレゼンスを持つ世界最大のテレビメーカーの1つです。同社の製品は、世界中の160以上の国と地域の消費者に届けられています。 「HisenseをHEVC Advance特許プールに迎え入れることを歓迎いたします」、とAccess AdvanceのCEOであるPeter Moller氏は語ります。「本件契約は、相当の期間にわたるチーム間の広範な関与の結実であり、Hisens...